Wegovy Pill Sets a Launch Record, and Novo Still Under-Grew an 85% US Obesity Market

Results vs. Consensus

Novo Nordisk reported before the European open on 6 May 2026 and hosted its call at 13:00 CEST, 7:00 AM ET the same day. The quarter has to be read twice: once as reported under IFRS, and once on the adjusted basis the company introduced with its 2025 full-year results and now guides against. The two tell opposite stories, and only one of them is informative.

Q1 2026 Scorecard (adjusted basis, DKK)

Year-over-Year Comparison

The reported column is what most headline coverage picked up: sales up 24% in kroner, operating profit up 54%, net profit up 67%, diluted earnings per ADR up 67% to DKK 10.91. None of that describes the business. All of it is the DKK 26,760M provision reversal flowing through the top line and straight to operating profit with no cash consequence whatsoever. The adjusted column is the business: a mid-single-digit constant-currency sales decline and a mid-single-digit constant-currency operating profit decline, with a further six-point drag in kroner from a stronger krone against the dollar.

Sequential Comparison

The sequential table is the cleanest window into what actually happened. Sales fell 11.5% and operating profit rose 3.5%. That is the entire quarter in two numbers. The Q4 2025 base is a fair comparison for operating profit because the DKK 8,014M of restructuring charges from the September 2025 transformation landed in Q3 2025, not Q4; the fourth quarter's restructuring line was a net credit of DKK 89M.

Segment Performance

Adjusted Sales by Geography

Adjusted Sales by Therapy Area

Obesity Care Versus Its Own Market

This is the table that decides the rating, and it is the company's own.

US Operations

US obesity care sales grew 9% at constant currency. The branded obesity market in the US grew volumes 85%. Injectable Wegovy sales in the US actually declined 11% at CER on lower realised prices, and the pill's DKK 2,256M of sales (all of it US, since ex-US launches have not yet happened) is what carried the segment to positive territory at all. Strip the pill out and US obesity care would have gone backwards in a market that nearly doubled its volume.

Sales growth and volume growth are different measures, and the honest caveat is that US realised prices fell hard enough to open a wide wedge between the two. But a 76-point gap is not a rounding difference. Even generous assumptions about price decline leave Novo's US obesity volumes growing well below the market's.

Assessment: The US obesity franchise is not participating in its own category's expansion, and the pill is currently masking that rather than reversing it. The pill's early volume is largely self-pay, which is where the lowest prices are, so the mix that fixes the share problem is also the mix that deepens the price problem. This is the central unresolved question in the name and Q1 did not answer it.

International Operations

International obesity grew 44% at CER against an 84% market, so the gap is narrower but present in the same direction. EUCAN grew 63% against an 80% market, helped by the Ozempic 2.0 mg rollout and early Wegovy 7.2 mg approvals. Region China went backwards, down 37%, following list-price reductions after a competitor's NRDL listing. Management disclosed roughly 55% weekly injectable GLP-1 volume market share in international markets and characterised it as declining but with the rate of decline stabilising.

"While our market share has been declining over recent quarters, we are starting to see our share growth stabilizing, indicating we are gradually seeing the benefit of our efforts to drive competitiveness." — Emil Kongshoej Larsen, EVP International Operations

Assessment: Credit where due: 44% growth on a large base with an 8-to-9-month-old full-supply position is real recovery, and the international story is directionally better than the US. But "stabilising" is a description of the second derivative. Share is still being lost, and the compound patent expiry on semaglutide across several international markets arrives before the share trend turns.

Diabetes Care

Diabetes fell 12% at CER, with US diabetes down 19% and international diabetes down 4%. Within that, US GLP-1 diabetes fell 16% at CER against a US GLP-1 diabetes market whose volumes grew 13%, and international GLP-1 diabetes fell 1% against a market up 40%. Ozempic fell 8% at CER globally, though international Ozempic grew 6% at CER on EUCAN volumes. Rybelsus fell 15% at CER globally and 27% in the US, which management attributed partly to a deliberate reprioritisation of promotional spend. Insulin fell 17% at CER, with US insulin down 36%.

"On Ozempic pricing in the U.S. — what we've seen in Q1 is a continuation of what we saw toward the end of last year, both on volume trending and on pricing, in the range of minus 10% to up to minus 15% price erosion." — Karsten Munk Knudsen, CFO

Assessment: Diabetes is the funding source and it is shrinking faster than obesity is growing. Diabetes is DKK 44.9 billion of the DKK 70.1 billion adjusted base, so a 12% constant-currency decline there is worth more than the 22% obesity growth on a DKK 20.9 billion base. This is the arithmetic behind the guided full-year decline, and it does not require anything to go wrong from here.

Rare Disease

Rare disease sales of DKK 4,215M fell 2% at CER, with US rare disease down 16% on de-stocking from year-end 2025 wholesaler buying patterns and international rare disease up 9%. The reported segment operating profit of DKK 1,618M at a 29.6% margin looks like a sharp recovery against DKK 544M and 11.8% a year ago, but it is not one: DKK 1,246M of the 340B reversal was allocated to this segment, which is the entire difference between its reported sales of DKK 5,461M and its adjusted sales of DKK 4,215M. Backing that out leaves roughly DKK 372M of underlying segment operating profit on adjusted sales, an approximately 8.8% margin against 11.8% a year ago. The segment's margin went down, not up. The etavopivat HIBISCUS readout is its real news.

Assessment: Six percent of sales and rising in strategic weight. The etavopivat data gives the segment a genuine first-in-class asset for the first time in years, and the CEO used the call to signal that rare disease is a deliberate third leg rather than a legacy tail. Immaterial to 2026 numbers, potentially material to the 2028 story.

Commercial KPIs

Key Topics & Management Commentary

Overall Management Tone: Confident and notably more concrete than the posture the company carried through 2025, with the launch metrics doing most of the persuasive work and the cost line supplying the rest. Management was willing to be specific where the news was good (script counts, titration, formulary parity) and framework-level where it was not, giving no quantification of the 2027 list-price reset, no US share figure, and no gross-margin disclosure on the pill. Analyst pushback clustered on two points, the durability of the cost base and the floor under oral pricing, and on both the answers were directional rather than numerical.

1. The 340B Reversal and Why the Reported Numbers Say Nothing

A USD 4.2 billion sales-rebate provision related to the US 340B Drug Pricing Program, previously constrained, was fully reversed in the quarter. In kroner that is DKK 26,760M, and it lands entirely in net sales, which means it flows dollar-for-dollar to gross profit and operating profit. Reported sales of DKK 96,823M and reported operating profit of DKK 59,618M both carry it. The balance sheet shows the mechanics plainly: current sales deductions and product returns fell to DKK 119,250M from DKK 133,349M at year-end.

There is no cash impact. The company was explicit about this in the announcement and Novo's CFO opened his prepared remarks by walking the reported line back to the adjusted line before saying anything else about the quarter.

"In the first 3 months of 2026, our reported sales increased by 32%, reaching DKK 96.8 billion. However, as part of our 2025 full year results, we introduced adjusted metrics to exclude certain exceptional and nonrecurring effects, primarily of noncash nature, including the provision reversal of USD 4.2 billion related to the 340B drug pricing program in the U.S." — Karsten Munk Knudsen, CFO

Assessment: The disclosure is clean and the company handled it correctly. The risk is not to Novo's reporting integrity but to the reader's: this quarter produces an income statement that will sit in databases and screens showing 32% constant-currency growth and 67% net-profit growth for a business that shrank. Anyone modelling from a data vendor rather than the filing will get 2026 badly wrong, and anyone screening on trailing growth will get a false signal for the next four quarters.

2. Wegovy Pill: The Best Launch, Minus the Pipeline Fill

The pill launched 5 January and by the week ending 17 April was running above 200,000 weekly prescriptions, up from around 50,000 as of 23 January. Cumulative prescriptions passed two million in sixteen weeks against more than one million patients treated. The company calls it the strongest-ever GLP-1 volume launch in the US and that claim looks defensible. All three of the largest pharmacy benefit managers added it at parity with injection on standard template formularies by quarter-end.

Against that, DKK 2,256M of first-quarter sales is not DKK 2,256M of demand. Under direct questioning the CFO sized the stocking component.

"For the Wegovy tablet, we reported around DKK 2.3 billion sales in Q1. To the tune of $150 million of those were related to what we call pipeline filling — both the initial inventory build with wholesalers and pharmacies, the customary launch orders, and the customary inventory build in connection with the brand getting bigger very, very fast." — Karsten Munk Knudsen, CFO

At the company's own conversion for the quarter (USD 4.2 billion stated as DKK 26.8 billion, or 6.371 kroner to the dollar), USD 150 million is close to DKK 1.0 billion, roughly two-fifths of the reported pill line. Underlying sell-through of approximately DKK 1.3 billion still cleared the DKK 1.16 billion the Street had modelled, but by around a tenth rather than by the 94% the headline comparison implied. The CFO also flagged that further inventory build will continue as the brand scales, which means the same wedge between shipments and demand persists into Q2.

Assessment: The launch is genuinely excellent on volume and the naive-patient mix is the single best datapoint in the quarter. The sell-in number is not the right one to extrapolate from, and anyone annualising DKK 2.3 billion into a DKK 9 billion 2026 pill franchise is starting from a base that is two-fifths channel. The right framing is roughly DKK 1.3 billion of underlying demand growing fast from a low base, which is good but is not the number the market reacted to at the open.

3. Pricing Posture: "We Have Priced This Product Correctly"

Self-pay pricing runs USD 149 to USD 299 per month depending on dose, with the lowest price on the 1.5 mg starter. Asked directly whether there is room to go lower on the mid-doses, the CEO declined to move and framed the current level as demonstrated-correct by volume.

"Price is dynamic and a function of volume uptake. Looking at our volume uptake, we believe we are at the sweet spot. At the current prices, we have had 2 million scripts after 16 weeks, more than 200,000 scripts per week despite competitors launching, with more than 1 million patients on our product. We have priced this product correctly. Of course, it's dynamic because if you look at this in a longer spectrum, getting to hundreds of millions of patients will require very different pricing. But for now, this is the right price." — Mike Doustdar, President and CEO

The second half of that answer matters more than the first. The CEO conceded, unprompted, that the long-run price required to reach the addressable population is materially below today's. That is the correct strategic read and it is also an admission that current pricing is a waypoint, not a floor.

Assessment: Management is defending price in the near term and telling you it comes down in the long term. For a stock whose bull case rests on volume compounding, the question is whether volume compounds faster than price falls, and the company has now told you both directions of travel without giving you the crossover. Q1 gives the first data point on the answer and it is not favourable: obesity volumes grew, obesity revenue grew 22% at CER, and total company revenue still fell.

4. The January 2027 List-Price Reset

Novo announced during the quarter that effective 1 January 2027 it will cut wholesale acquisition cost on Wegovy injection 2.4 mg and 7.2 mg, Wegovy tablets up to 25 mg, Ozempic injection 0.5/1/2 mg, and Ozempic pill 7 mg and 14 mg to USD 675. That is approximately a 50% reduction for Wegovy and approximately 35% for Ozempic, applying to all doses. The company stated the change is expected to impact cash flow in 2027.

This sits alongside the November 2025 Most Favoured Nations agreement with the US Administration, which broadens Medicare Part D, Medicaid and direct-to-patient self-pay access. The Medicare Part D obesity pilot is scheduled to begin implementation on 1 July 2026.

Assessment: A 50% list-price cut is not a 50% net-price cut, because gross-to-net discounts collapse alongside list. But it is the largest single modelling variable in the name and it received one paragraph in a 33-page announcement and no quantification on the call. The offset is volume through Part D and Medicaid, which is real and which management is clearly betting on. The timing is the problem: the price cut is dated, the volume is assumed, and the gap between them lands squarely in the 2027 numbers that a stock trading on next-twelve-month earnings is already discounting.

5. Losing Share in a Market Growing 85%

Novo's own IQVIA-sourced table puts US branded obesity market volume growth at 85% and its own US obesity care sales growth at 9% at constant currency. International: market volumes up 84%, Novo up 44%. In GLP-1 diabetes the pattern repeats: the US market grew volumes 13% while Novo's US GLP-1 diabetes sales fell 16%, and the international market grew 40% while Novo's international GLP-1 diabetes sales fell 1%.

Management addressed the international side of this directly and described share as declining with the decline stabilising, citing telehealth partnerships now representing around 20% of Wegovy sales in some of its largest markets and the Ozempic 2.0 mg rollout as the tools. The US side went unquantified.

Assessment: Price erosion explains part of the wedge between sales growth and volume growth and cannot explain all of it. This is the bear case stated in the company's own numbers, and it is the reason a 22% constant-currency obesity growth rate does not read as a good result. Novo is growing obesity revenue meaningfully slower than the category is growing volume, in every region it discloses, in a quarter when it launched the best-selling new product in the category's history.

6. Wegovy HD and the Efficacy Reset

The FDA approved semaglutide 7.2 mg as Wegovy HD on 19 March under the Commissioner's National Priority Voucher pilot, and Novo launched it nationwide on 7 April across more than 70,000 pharmacies, telehealth providers and NovoCare Pharmacy. The three largest PBMs added it as a line extension on standard formularies. STEP UP showed 20.7% mean weight loss when taken as intended, with roughly one in three patients reaching 25% or more, and a discontinuation rate on adverse events similar to the 2.4 mg dose. The UK approved the 7.2 mg single-dose device on 14 April; an EU decision is expected around summer with more than 20 international launches to follow.

"Our recent commercial efforts have driven a notable shift in new-to-brand prescription dynamics — the Wegovy franchise is now leading on NBRx market share with a share of around 65%." — Jamey Millar, EVP US Operations

Assessment: This is the most under-discussed positive in the quarter. For two years the bear case on Wegovy versus tirzepatide has been an efficacy gap; 20.7% substantially closes it, and doing so with an unchanged tolerability profile is the part that matters commercially. A 65% new-to-brand share, if it holds, is a leading indicator that turns into revenue share over the following four to six quarters. It is also the single most plausible route to the share stabilisation management is claiming.

7. The Cost Line, and What Is In It Only Once

Sales and distribution costs fell 13% at constant currency to DKK 12,077M, or 17.2% of adjusted sales, against 19.1% in Q1 2025 and 20.1% in Q4 2025. Three things drove it: a legal-provision release, savings from the 2025 company-wide transformation, and headcount now roughly 10,000 lower year on year at around 68,000 full-time equivalents. Asked why spend was falling into a launch, the CFO led with the one-off.

"On SG&A — first, it's important to note we have a one-off favorable adjustment of a legal provision, a notch more than $100 million that favorably impacts the quarter. One should adjust for that. We have gone pretty much all in on the Wegovy pill launch and its resourcing. The model we're deploying together with telehealth partners yields a different scalability in terms of promotional presence between paid versus earned media, yielding a very high share of voice in Q1. Through the coming quarters, expect us to be disciplined around our spending. We have fewer employees, which helps on SG&A, but we are truly investing in the growth drivers — Wegovy HD, the launch products coming up, and the Wegovy tablets. The SG&A ratio for the full year is in the low 20s." — Karsten Munk Knudsen, CFO

The last sentence is the one to model. A full-year ratio in the low 20s against Q1's 17.2% requires the remaining three quarters to run at roughly 22% on our estimates, a step-up of around five points from the Q1 level. On a sales base of the size implied by the guidance range, that is several billion kroner of incremental spend already committed and not yet visible.

Assessment: The cost discipline is real and the transformation is delivering, but the Q1 margin is not the run rate and management said so plainly. Investors extrapolating a 46.9% adjusted operating margin should note that the company's own full-year guidance implies materially lower margins across the balance of the year, and that the arithmetic of a low-20s sales and distribution ratio plus a rising research ratio is what closes the gap between Q1's result and a guided full-year operating-profit decline of 4% to 12%.

8. Research Spend Was Light and Is Going Up

Research and development costs of DKK 10,284M were flat in kroner and up 4% at constant currency, running at 14.7% of adjusted sales against 13.2% in Q1 2025 and 18.5% in Q4 2025. Pressed on phasing, the CFO gave an unusually clear steer.

"As Martin mentioned, there's a lot going in R&D, and it's a strategic priority to expand our pipeline for growth not only medium term but long term. The R&D ratio in Q1 is a notch on the low side compared to what we expect for the full year, so expect us to lean in on R&D investment in the coming quarters." — Karsten Munk Knudsen, CFO

The commitments backing that are specific: the zenagamtide AMAZE Phase 3 programme is running, a CagriSema high-dose Phase 3b starts in Q2, AMAZE 9 for oral zenagamtide starts in Q3, a cagrilintide high-dose Phase 3 starts in Q4, and the AMBITION Phase 3 programme in diabetes starts in Q4. Guidance also embeds spend related to the Akero acquisition.

Assessment: Two cost lines were light in Q1 and both were flagged as going higher. Taken together, the sales and distribution step-up and the research step-up account for most of the distance between a 46.9% first-quarter margin and the full-year guide. That is not a criticism of the spending, which is aimed at the right assets. It is a warning against treating Q1's operating leverage as a new baseline.

9. Loss of Exclusivity Has Started

Semaglutide generics launched in India during the quarter. In Canada two generics have been approved but none launched; in Brazil none has launched. Management stated group guidance assumes a low-single-digit impact and described a savings-card tactic in Canada with strong uptake on both Ozempic and Wegovy, plus optionality on a second brand. The rule of the Canadian market was laid out plainly: after three generics enter, a mandated 65% price decline versus list applies.

"We now have 2 approved generics in Canada. We haven't changed our guidance at group level, which assumes low single-digit impact at group level. We are very ready — the leading tactic in Canada is a savings card that has seen very good uptake for both Ozempic and Wegovy, giving us a lot of maneuverability as this unfolds." — Emil Kongshoej Larsen, EVP International Operations

Assessment: The near-term financial exposure is genuinely small and management's preparation looks credible. The strategic signal is larger than the 2026 number: semaglutide is now a molecule with a generic clock running, in a franchise where the successor assets (CagriSema, zenagamtide) are not yet approved. Every quarter of delay in the successor pipeline is a quarter in which more of the base is exposed.

10. Manufacturing Scale as the Remaining Moat

Asked whether synthesis-route generics eventually erode Novo's unit-cost advantage, the CFO made the strongest version of the manufacturing argument and then declined to translate it into a pricing conclusion.

"On sema manufacturing — we believe we are hypercompetitive in terms of unit cost and hypercompetitive in terms of scale to produce sema globally. What that leads into in terms of pricing in different healthcare systems remains to be seen. More of this will be available in care segments with different partners and go-to-market models. Brand recognition and loyalty versus generics, and consequently how much price differentiation next-generation products can achieve, remains to be seen. India is not a good proxy for other markets." — Karsten Munk Knudsen, CFO

The supply constraint on the pill is the flip side of the same argument. Management confirmed the pill is not in unlimited supply because of product design, and framed the ex-US rollout pace as deliberately gradual for that reason.

Assessment: Scale in peptide API is the most durable competitive asset Novo owns, and the DKK 55 billion 2026 capex programme is aimed squarely at extending it. The honest limitation is that a manufacturing cost advantage protects gross margin in a price war; it does not protect revenue. In a category where the branded market is growing volumes 85% and Novo's revenue is falling, cost advantage is the wrong lever for the problem currently in front of the company.

11. Guidance: A One-Point Parallel Shift

Both ends of both ranges moved up by exactly one percentage point. Adjusted sales growth at CER goes to minus 4% through minus 12% from minus 5% through minus 13%; adjusted operating profit growth does the same. The currency drag also improved, from roughly three points to roughly two on sales and from roughly five points to roughly three on operating profit. Free cash flow guidance rose to DKK 36 to 46 billion from DKK 35 to 45 billion. Financial items guidance deteriorated sharply, to a loss of around DKK 0.6 billion from a gain of around DKK 2.3 billion. Effective tax rate (21% to 23%) and capex (around DKK 55 billion) were unchanged.

"Now 3 months down the road, we've seen several items play our way: oral script trends, the Wegovy high-dose approval, our decision to launch Wegovy tablet ex U.S. in a few select markets, and more information on competition and LOE approvals in IO. Based on that, we're more confident in our outlook, and as a consequence, we parallel shifted both sales and OP ranges by 1 percentage point. You should take it as a signal of confidence that we lifted the range by 1 percentage point." — Karsten Munk Knudsen, CFO

Assessment: The refusal to lift the low end is the informative half. Management raised the ceiling and the floor together rather than narrowing the range, which means nothing has been de-risked; the whole distribution simply moved a point. After the strongest product launch in the category's history, a guidance revision worth one percentage point on an eight-point range is a modest verdict on how much of 2026 the pill actually changes. The improvement in free cash flow guidance is worth more than it looks, coming as it does alongside a DKK 2.9 billion deterioration in guided financial items.

Guidance & Outlook

The company also disclosed that on a non-adjusted basis, the midpoints of 2026 sales and operating profit growth guidance at CER would be positive 1% and positive 12% respectively. That is the 340B reversal talking, and the fact that Novo felt the need to footnote it tells you the company expects the reported-versus-adjusted confusion to persist all year.

Implied quarter-over-quarter ramp: Q1 adjusted sales of DKK 70,063M against a full-year guide of minus 4% to minus 12% at CER, with roughly a two-point currency drag, implies full-year adjusted sales roughly 6% to 14% below the DKK 309,064M recorded in 2025. That puts the remaining three quarters at roughly DKK 196 to 221 billion combined, or DKK 65 to 74 billion per quarter, against Q1's DKK 70.1 billion. The revenue line is therefore guided to be roughly flat to modestly lower sequentially for the balance of the year, with the pill and Wegovy HD ramps offsetting continued price erosion rather than driving growth on top of it.

Street at: Sitting at the print, consensus was clustered around the middle-to-upper half of the prior guidance band and had to shift up mechanically with the raise. The operating-profit line is where the gap is widest: Q1's DKK 32,858M against a full-year guide implying roughly DKK 109 to 119 billion means the remaining three quarters average around DKK 25 to 29 billion, materially below Q1's level. Anyone carrying Q1's margin forward is carrying a number the company has already guided away from.

Guidance style: Conservative and deliberately so. This management team inherited a credibility problem from 2025 and has chosen wide ranges and small increments. The parallel shift rather than a narrowing is the tell: with one quarter done and a launch outperforming, a confident team narrows the band. This one moved it instead.

Analyst Q&A Highlights

Titration Drop-Off on the Oral Product, and Whether Supply Can Support an International Rollout

The opening question of the call went straight at the weakest observable point in the pill data: an apparent fall-off in patients moving from the 4 mg to the 9 mg dose, and whether that reflects the price step, tolerability, or insufficient weight loss. The second half asked how many international markets the supply chain can sustain. Management answered the titration point by asserting comparability to injectable Wegovy without providing the underlying rates, and answered supply by conceding the constraint and framing the international pace as a choice rather than a limit.

Q: "Two questions on oral Wegovy. There seems to be a drop-off in patients going between the 4mg and 9mg doses in titration. Is that the jump in price, tolerability, or weight loss results? And how will that impact stay time and growth going forward? And on supply of oral Wegovy — how many international markets do you think you can sustain?"
— Richard Vosser, JPMorgan

A: "Richard, on supply — while we do not have unlimited supply for the Wegovy pill due to product design, despite setting a new record for product uptake in the U.S., we are still able to announce launches in the first markets ex U.S. already this year. This speaks to scaling of supply and the inventories we've put in place, and we play it gradually from here in terms of the pace of international rollout."
— Karsten Munk Knudsen, CFO

Assessment: The supply answer was candid and the titration answer was not. "Titration is happening as expected and comparable to what we see with injectable Wegovy" is an assertion, not a disclosure, and the question was specifically about a pattern the questioner could already see in the data. Stay time and dose mix are the two variables that convert a script number into a revenue number, and neither was quantified anywhere on the call.

Why Selling Costs Fell Into a Launch Quarter

The most commercially important exchange of the call. Absolute sales and distribution spend was the lowest in several quarters at the exact moment the company was executing its largest launch, which is either a new and structurally cheaper commercial model or a one-off. Management led with the one-off, sized it, and then set the full-year ratio.

Q: "First, on SG&A — it's the lowest absolute number for a number of quarters, which seems odd into a product launch. Should we think of this as a new commercial model with telehealth as the base, or think about the cadence of SG&A through the year?"
— Sachin Jain, Bank of America

A: "On SG&A — first, it's important to note we have a one-off favorable adjustment of a legal provision, a notch more than $100 million that favorably impacts the quarter. One should adjust for that. We have gone pretty much all in on the Wegovy pill launch and its resourcing. The model we're deploying together with telehealth partners yields a different scalability in terms of promotional presence between paid versus earned media, yielding a very high share of voice in Q1."
— Karsten Munk Knudsen, CFO

Assessment: Credit for volunteering the provision release rather than letting the ratio speak for itself. The telehealth point is the genuinely new information: if earned media through telehealth partners can carry share of voice at materially lower cost than a traditional sales force, that is a structural margin argument. But the full-year low-20s guide says management is not yet willing to bank it, and neither should anyone else.

Whether the Oral Price Points Are a Floor or a Waypoint

A recurring line of questioning across the call probed whether USD 149 to 299 is defensible, and what happens to blended pricing as mix shifts toward the cheaper oral product. The answer was the most strategically revealing statement management made.

Q: "A broad question on price — you've mentioned no intention to lower prices and oral price in the sweet spot. Is there no intention to lower at the 150 or 149 lower oral dose holding? And if oral price is the sweet spot, how do we think about price mix across the business shifting to this lower price bracket?"
— Sachin Jain, Bank of America

A: "Price is dynamic and a function of volume uptake. Looking at our volume uptake, we believe we are at the sweet spot. At the current prices, we have had 2 million scripts after 16 weeks, more than 200,000 scripts per week despite competitors launching, with more than 1 million patients on our product. We have priced this product correctly. Of course, it's dynamic because if you look at this in a longer spectrum, getting to hundreds of millions of patients will require very different pricing. But for now, this is the right price."
— Mike Doustdar, President and CEO

Assessment: The mix half of the question went unanswered, which is the half that matters for 2027 and beyond. Every incremental oral script at USD 149 to 299 replaces or forgoes an injectable script at a higher realised price, and the company has now confirmed both that the shift is happening and that the long-run price is lower still. The bull case requires volume elasticity to more than compensate; management asserted it and did not evidence it.

Why the Bottom of the Guidance Range Did Not Move

A pointed challenge on the shape of the raise: with a quarter delivered above plan, why did the floor of a double-digit decline survive? The response enumerated what had gone right without naming what could still go wrong.

Q: "On guidance — Karsten, you haven't changed the lower end of the range when Q1 came in quite robustly. What are the variables that don't allow you to lift that lower end from a double-digit decline?"
— Michael Leuchten, Jefferies

A: "Now 3 months down the road, we've seen several items play our way: oral script trends, the Wegovy high-dose approval, our decision to launch Wegovy tablet ex U.S. in a few select markets, and more information on competition and LOE approvals in IO. Based on that, we're more confident in our outlook, and as a consequence, we parallel shifted both sales and OP ranges by 1 percentage point. You should take it as a signal of confidence that we lifted the range by 1 percentage point."
— Karsten Munk Knudsen, CFO

Assessment: The question was about the floor and the answer was about the ceiling. Instructing the listener how to interpret a guidance move ("you should take it as a signal of confidence") is a substitute for the substantive answer, which would have been to name what still sits in the low case. On the same call management confirmed US Ozempic price erosion running at 10% to 15%, a Medicaid coverage reduction, an MFN agreement, and semaglutide generics in India with Canada approved. Those are the variables, and management declined to rank them.

Sizing the Channel Fill in the Oral Launch Number

The question that produced the most useful number of the call. Having seen the reported pill line come in at roughly double the polled figure, a direct request to quantify the inventory component drew a specific answer and a forward warning.

Q: "Can you quantify the total inventory impact on Wegovy pill sales in the quarter? Was there further inventory increase through the quarter, and do you expect that to run off or continue building in subsequent quarters?"
— Graham Parry, Citigroup

A: "For the Wegovy tablet, we reported around DKK 2.3 billion sales in Q1. To the tune of $150 million of those were related to what we call pipeline filling — both the initial inventory build with wholesalers and pharmacies, the customary launch orders, and the customary inventory build in connection with the brand getting bigger very, very fast. This happens for all products; it's just a question of the pace of the inventory build. Going forward, there will be a certain degree of inventory build as the brand continues to expand, so IQVIA scripts will show additional sales especially in early phases linked to inventory build across the chain — this happens for all products and we've seen it for decades."
— Karsten Munk Knudsen, CFO

Assessment: The best-handled question on the call and the most consequential for models. Management gave a real number when it would have been easy to deflect, and the follow-through matters as much: channel build continues, so the wedge between shipments and prescriptions persists into Q2 rather than reversing. Anyone building an oral franchise forecast off the Q1 print without this haircut is starting roughly two-fifths too high.

The 47% Margin Versus a 40% Full-Year Implied Margin

An analyst walked the arithmetic publicly: even adjusting for the legal one-off, the quarter delivered a mid-40s adjusted operating margin while the guidance midpoint implies roughly 40%. Management did not dispute the gap and reframed it as a deliberate choice rather than a deterioration.

Q: "You achieved a 47% adjusted EBIT margin; even with the legal one-off, it's still mid-40s. But the midpoint of the full year guide is more like 40%. Is that because of more R&D, or also lots more sales and marketing for ex-U.S. oral Wegovy launches?"
— James Gordon, Barclays

A: "On margins — our point of departure is already a very competitive margin compared to peers. Strategically, for us it's more important to invest in future growth than short-term margin optimization. We're investing in the short and medium term opportunity with assets in market or coming soon, as well as investing in pipeline. We could drive for higher margin, but that's not our strategy or intention. We are very disciplined and rational — almost 10,000 fewer FTEs today compared to a year ago, reallocating resources toward our key growth opportunities."
— Karsten Munk Knudsen, CFO

Assessment: An honest answer that confirms the Q1 margin is not the run rate, and a defensible strategic position given the pipeline in front of the company. The exchange also confirms the guidance is not sandbagged on the cost line: management intends to spend the difference, which removes the most common bull argument for an upside surprise later in the year.

The Canadian Generic Playbook and the International Exclusivity Cliff

With two semaglutide generics approved in Canada and none yet launched, the question was how much of that is in guidance and how prepared the commercial organisation is. The answer laid out the mechanics of the market with unusual specificity.

Q: "On the impact of generic semaglutide in Canada — how are you thinking about that in your guidance?"
— Evan Seigerman, BMO Capital Markets

A: "We now have 2 approved generics in Canada. We haven't changed our guidance at group level, which assumes low single-digit impact at group level. We are very ready — the leading tactic in Canada is a savings card that has seen very good uptake for both Ozempic and Wegovy, giving us a lot of maneuverability as this unfolds. After 3 generics, there is a mandated 65% price decline versus our list — we know the game there and are ready to play it. We have optionality on a second brand as well."
— Emil Kongshoej Larsen, EVP International Operations

Assessment: The most operationally confident answer on the call, and the disclosure of the mandated 65% price decline at the third generic is genuinely useful because it converts an open-ended risk into a dated, quantified one for that market. The caution is that "low single-digit impact at group level" is doing a lot of work across India, Canada and Brazil combined, and it was stated as an assumption rather than a modelled range.

What They're NOT Saying

1. Any quantification of the January 2027 list-price reset. A roughly 50% WAC reduction on Wegovy and roughly 35% on Ozempic, effective on a known date, received one paragraph in the announcement, no slide, and no question-and-answer time. The only forward statement is that it "is expected to impact Novo Nordisk's cash flow in 2027." Net-price impact, volume offset, and gross-to-net mechanics were all left to the reader.
2. Wegovy pill gross margin. An oral peptide at USD 149 to 299 per month carries a different cost structure and a different realised price than an injectable at multiples of that. With the pill now roughly 42% of US Wegovy scripts, its margin is the single biggest driver of the consolidated gross-margin trajectory, and it was neither disclosed nor asked about.
3. US obesity market share. Management gave an international injectable GLP-1 volume share (~55%) and a US new-to-brand share (~65%), but no US obesity total volume or value share. Given that US obesity sales grew 9% against 85% market volume growth, the omitted number is the one that would settle the debate.
4. Stay time, persistence and refill rates on the pill. Management said it is "tracking titration, refills and stay time" and that it is "encouraged by what we see, consistent with our expectations," without a single rate. For an oral product where the discontinuation risk profile differs from injection, these are the metrics that determine whether two million scripts becomes a durable franchise.
5. The size of the legal provision release, precisely. "A notch more than $100 million" is a range, not a figure, on an item material enough that the CFO instructed listeners to adjust for it. The exact amount would have let analysts compute the underlying sales and distribution ratio directly.
6. Next-generation GLP-1 differentiation. Asked whether the internal next-generation asset differentiates on dosing frequency or on efficacy and safety, the R&D head listed the four possible axes and then deferred to a future capital markets day. That is a reasonable answer for a competitive-sensitivity reason and it is still a deferral.
7. Any financial framing of the securities class action. The amended complaint filed 3 April 2026 covers ADR purchasers from 6 November 2024 to 28 July 2025 and names the company, the former CEO, and the sitting CFO. The announcement states the company does not expect a material impact. It received no call time.
8. Commercial framing for CagriSema. With a US regulatory decision expected at the end of 2026 and a potential 2027 launch, the call covered CagriSema's trial mechanics and the termination of the co-formulation, but offered nothing on pricing, positioning against the existing Wegovy portfolio, or the cannibalisation question that a third obesity product in the same bag inevitably raises.

Market Reaction

• Pre-print setup: The ADR closed at $44.87 on 5 May, down 11.8% year to date against the S&P 500's +6.0%, down 32.3% over the trailing twelve months, but up 22.4% over the trailing thirty days from $36.67 on 6 April. The 52-week closing range entering the print was $35.29 to $81.05, so the stock came into the quarter having already recovered roughly a quarter off its low.
• Reaction session (6 May, before-the-open reporter): Opened at $46.31, a 3.2% gap up, traded a range of $45.53 to $47.55 (+1.5% to +6.0%), and closed at $45.76, up 2.0% or $0.89. The S&P 500 rose 1.5% the same session, so the relative move on a 14% operating-profit beat and a guidance raise was roughly half a percentage point.
• Volume: 30.9 million ADRs against a 17.1 million thirty-day average, or 1.8x normal.
• Copenhagen cross-check: The primary listing traded up 6.7% in morning trading and closed roughly 2.3% higher, the same open-and-fade pattern the ADR tape shows.

The fade is the message. The stock was handed the three things that normally produce a durable move: a large operating-profit beat, a raised full-year outlook, and a launch metric at roughly double what the Street had modelled. It gave back roughly two-thirds of its peak intraday gain by the close and finished half a point ahead of the index. That is a market pricing the beat as low-quality, and reading the tape against the filing, it is right to.

What the market worked out during the session. Three things become visible only after the numbers are read carefully rather than off the headline. First, the reported income statement is inflated by a non-cash provision reversal, so the 32% and 67% growth figures that led the wires describe nothing. Second, roughly two-fifths of the pill's DKK 2,256M was channel fill, disclosed on the call rather than in the release, which reduces a 94% beat to something closer to a 12% beat on underlying demand. Third, the guidance raise was a one-point parallel shift with the floor untouched, which is a smaller vote of confidence than a raise normally represents. Each of those lands sequentially through a trading day, and the intraday chart follows that order.

Positioning context. The 22.4% thirty-day run into the print matters. A stock that has already rallied more than a fifth in a month has spent much of the "bad news is priced in" argument before the news arrives, and the marginal buyer at $46 is underwriting a recovery rather than buying a dislocation. Against a still-negative twelve-month move of 32.3%, this print did not settle which of those two frames is correct.

Street Perspective

Debate: Is the Oral Product an Offset to Price Erosion, or the Vehicle That Delivers It?

Bull view: The pill is category expansion, not substitution. Roughly 80% of users are GLP-1 treatment-naive, all three major PBMs granted parity formulary placement within the launch quarter, and the franchise leads new-to-brand share at around 65%. Each of those points to the pill enlarging the treated population at a price point that unlocks patients an injectable at prior pricing never reached.

Bear view: A course of therapy at USD 149 to 299 per month is a fraction of prior injectable economics, the CEO has said on the record that reaching the addressable population "will require very different pricing," and a January 2027 WAC reset of roughly 50% on Wegovy is already announced. The pill is the mechanism by which the category's price level resets downward, and Novo is running the reset on itself.

Our take: The bear framing is closer to right on the mechanism and the bull framing is closer to right on the direction. Both can be true, and the resolution is arithmetic rather than narrative: does treated-population growth outrun realised-price decline? Q1 is the first quarter with the pill in the base and the answer was no. Obesity care grew 22% at constant currency, total adjusted sales fell 4%, and the company guides to a full-year decline on both lines. Until a quarter shows volume winning that race, the offset is an assumption.

Debate: Does Roughly 14x Next-Twelve-Month Earnings Already Discount the 2027 Reset?

Bull view: The multiple sits at roughly half the closest comparable in the category, on a business with a 46.9% adjusted operating margin, DKK 12.8 billion of quarterly free cash flow, and the second-best obesity asset portfolio in existence. A next-twelve-month window that already reaches into 2027 means the price reset is inside the earnings estimate the multiple is struck against, not ahead of it.

Bear view: A multiple that low on a company guiding to shrink is not obviously cheap; it is the market declining to capitalise an earnings stream it cannot yet see stabilising. The de-rating from the 2024 peak has been continuous rather than a single dislocation, which is the signature of a structural re-rating rather than a sentiment overshoot, and consensus 2027 numbers have not yet been struck against a fully-modelled 50% list-price cut.

Our take: The valuation is genuinely undemanding and that is why this is a Hold rather than an Underperform. But the bear framing has the better of the specific point: the reset is dated and the volume offset is not, so the earnings base the multiple is applied to has an identifiable downward revision still to come. Cheap against a falling estimate is not the same as cheap.

Debate: Is the Share Loss Cyclical or Structural?

Bull view: The share loss was manufactured by two fixable problems, a supply shortfall that is now resolved after eight to nine months of full supply, and an efficacy gap that Wegovy HD's 20.7% closes. With both remediated, a 65% new-to-brand share is the leading indicator that share stabilises and then recovers over the following four to six quarters. Management is already describing the international decline as stabilising.

Bear view: Novo under-grew its market in the US, in EUCAN, in emerging markets, in APAC, and in China, in the same quarter that it launched the best-selling new product the category has seen. If the problem were supply or efficacy, at least one geography would have kept pace. A competitor with a superior injectable, a newly launched oral, and a deeper primary-care commercial footprint is simply taking the category.

Our take: The bull argument is the more testable and the next two prints will settle it, because new-to-brand share genuinely does lead total share by roughly a year. The bear argument holds the stronger evidence today: the breadth of the under-growth across five disclosed regions is not what a supply or efficacy explanation predicts. We would need to see US obesity growth close a meaningful part of the gap to the market's volume growth before treating the share loss as cyclical.

Model Update Needed

This is initiation of coverage and no prior Aardvark Labs model exists for the name. The table below states the assumptions we are opening with rather than changes to a standing model.

Valuation framework. Working from the guided adjusted operating-profit range of roughly DKK 109 to 119 billion, deducting the guided DKK 0.6 billion net loss on financial items, adding back amortisation on intangible assets of approximately DKK 6.5 billion (excluded from adjusted net profit but not from adjusted operating profit), and applying a 22% tax rate against 4,448.7 million diluted shares, gives 2026 adjusted EPS of roughly DKK 20.2 to 21.9, with a midpoint near DKK 21.0. At the company's own conversion rate of 6.371 kroner to the dollar, that is roughly $3.17 to $3.44 per ADR with a midpoint near $3.30. Against the $45.76 close the ADR therefore trades at approximately 13.9x our 2026 midpoint. We do not build the estimate by applying the guided growth rate to 2025 adjusted EPS: the two are struck on different definitions, and the 2025 adjusted EPS figure adds back a major restructuring charge that adjusted operating profit does not.

Fair value range: $40 to $50, midpoint $45. The range applies 12x to 15x to the 2026 midpoint estimate. The low end implies -12.6% from the $45.76 close, the midpoint implies -1.7%, and the high end implies +9.3%. A multiple above 15x requires evidence that 2027 earnings grow rather than decline through the list-price reset, which no disclosure in this quarter supports. A multiple below 12x requires believing the franchise is impaired rather than repriced, which the launch data contradicts.

Thesis Scorecard Post-Earnings

This is initiation of coverage, so the pillars below are established here rather than carried forward, and the status column grades them against this quarter's print and call.

Overall: The thesis opens balanced with the evidence tilted slightly negative. Both confirmed bull pillars are about products and pipeline, which is where this company remains excellent. Both confirmed bear pillars are about price and share, which is where the revenue line is actually decided. A quarter in which the best product launch in the category's history coincided with under-growth in every region and a guided full-year decline is not a quarter that resolves the debate in either direction.

Action: Hold. The valuation is undemanding enough that we would not be short, and the share and price evidence is negative enough that we would not pay up. We would revisit toward Outperform on either of two specific developments: a quarter in which US obesity revenue growth closes a meaningful part of the gap to US branded obesity market volume growth, or a quantified 2027 bridge that shows Part D and Medicaid volume more than offsetting the January list-price reset. We would revisit toward Underperform if the pill's underlying sell-through, stripped of channel build, fails to grow sequentially in Q2, or if the international share decline resumes after management's stabilisation claim.